about
Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trialCarotid artery ultrasonographic assessment in patients from the Fremantle Diabetes Study Phase II with carotid bruits detected by electronic auscultation.Diagnostic criteria for depression in type 2 diabetes: a data-driven approach.The relationship between hypomagnesemia, metformin therapy and cardiovascular disease complicating type 2 diabetes: the Fremantle Diabetes StudyAspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study.Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea.A comprehensive investigation of variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/R2), and their association with serum adiponectin, type 2 diabetes, insulin resistance and the metabolic syndrome.Incidence and predictors of hospitalization for bacterial infection in community-based patients with type 2 diabetes: the fremantle diabetes study.Clinical impact of the temporal relationship between depression and type 2 diabetes: the Fremantle diabetes study phase IIClinical features and outcome in children with severe Plasmodium falciparum malaria: a meta-analysis.Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up studyTemporal changes in the prevalence and associates of diabetes-related lower extremity amputations in patients with type 2 diabetes: the Fremantle Diabetes StudyPrevalence, characteristics, and prognostic significance of HFE gene mutations in type 2 diabetes: the Fremantle Diabetes Study.Predictors of cognitive decline in older individuals with diabetes.Serum bicarbonate concentration and the risk of cardiovascular disease and death in type 2 diabetes: the Fremantle Diabetes StudyThe Structured Interview for Insight and Judgment in Dementia: Development and validation of a new instrument to assess awareness in patients with dementia.A Randomized, Placebo-Controlled, Double-Blind Efficacy Study of Nefiracetam to Treat Poststroke Apathy.Apolipoprotein E genotype and mortality in Southern European and Anglo-Celt patients with type 2 diabetes: the Fremantle Diabetes Study.Dementia onset, incidence and risk in type 2 diabetes: a matched cohort study with the Fremantle Diabetes Study Phase I.Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts.Comparison of anthropometric measures as predictors of cancer incidence: A pooled collaborative analysis of 11 Australian cohorts.Excess Risk of Dying From Infectious Causes in Those With Type 1 and Type 2 Diabetes.Prevalence of depression and its associations with cardio-metabolic control in Aboriginal and Anglo-Celt patients with type 2 diabetes: the Fremantle Diabetes Study Phase II.Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study.Determinants of diabetes-attributable non-blood glucose-lowering medication costs in type 2 diabetes: the Fremantle Diabetes Study.Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle Diabetes Study.Cost-effectiveness of artemisinin-naphthoquine versus artemether-lumefantrine for the treatment of uncomplicated malaria in Papua New Guinean children.Temporal changes in glycaemic thresholds for treatment intensification in type 2 diabetes in an urban Australian setting: The Fremantle Diabetes Study.Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase II.Risk and associates of incident hip fracture in type 1 diabetes: The Fremantle Diabetes Study.The prevalence of monogenic diabetes in Australia: the Fremantle Diabetes Study Phase II.Earlier age of dementia onset and shorter survival times in dementia patients with diabetes.Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: The Fremantle Diabetes Study Phase II.The utility of the Diabetes Anxiety Depression Scale in Type 2 diabetes mellitus: The Fremantle Diabetes Study Phase II.Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease.Prevalence of diabetes in Australia: insights from the Fremantle Diabetes Study Phase IIAge-related differences in glycaemic control, cardiovascular disease risk factors and treatment in patients with type 2 diabetes: a cross-sectional study from the Australian National Diabetes AuditClinical risk factors for depressive syndrome in Type 2 diabetes: the Fremantle Diabetes StudyIncidence, Risk Factors, and Outcomes of Intra-Abdominal Hypertension in Critically Ill Patients-A Prospective Multicenter Study (IROI Study)Does femoral venous pressure measurement correlate well with intrabladder pressure measurement? A multicenter observational trial
P50
Q28542921-0D83A582-37C2-42F7-8E20-569AA3D286A9Q30403703-667368C5-20AA-4EC5-A54F-7579ADF8CE4CQ30868913-434E0ADD-41B0-4519-94F4-795B504AB328Q31138001-0D9CD71B-383E-4FCC-B0EB-ED2D720FB39AQ33602214-F4F46450-74D5-4063-8570-A6544C7C7B54Q33838360-09C519F2-DAC5-4104-B06D-7583BBE9E1BEQ34564046-AC0AD90E-731B-49EB-88CB-E364BDFC9264Q34639959-9480BFA2-8EBD-4EBC-856A-9702EB1A920DQ35063933-7F20F3BB-D5CB-47BC-89CE-6A0406A87BFDQ35091391-EEDE3BD7-35E6-4625-9167-A6E57401ADC0Q35218484-283FA535-0134-408E-B6DC-9302F73E6CC7Q36383377-7F146294-2B0F-4A9F-828F-C3C5161A1B21Q36842036-66990396-2001-40C2-A3E1-7BCAB2EA908FQ36945266-F69E396E-CA18-4051-A366-CA3C18B002E6Q37319601-D4326A2B-E7FE-4D85-B67C-31DFBEA94F9BQ37629369-B65EB973-DAF4-4628-ADC1-837784EFE1F8Q38410138-ABEF09A9-11D1-4B53-819A-32656A4FB348Q39944998-3D517EB5-F6C5-4005-B799-A5530177D919Q40549777-F7CD7F5A-BBF6-4811-BAB2-2568FC0419C2Q41078855-203D1CB1-BF8B-4303-9A6A-DBBC63ADB0E1Q41158298-CEA6DBF8-5CCA-4A30-81C5-0E74EF65F4D3Q41164894-692C0EEE-49FE-4368-AFE2-77BA2EDF0864Q41471672-86DD775E-EB10-41B0-B5B8-29469E4A9CF9Q44779321-BE08CE0B-B81D-4C74-B269-49E1E6AB039AQ45242341-718A56BE-12C1-469C-BA07-DFA86BB77F2AQ45913065-96291E4A-3B2A-47A5-AB9A-2AA4251C1A2EQ47143596-D2723C87-7F08-4DB5-BA08-EA3FAE17C0DFQ47325486-0EB1F585-8847-490E-AC75-3017E455FF7AQ48217634-9094FCAB-E64B-4D80-B98C-5FAEB333EB8EQ50062286-40D5552F-FC3C-4F25-94EF-9DAE34DA0228Q50095179-01971819-6A22-49AC-900B-EDC66C874D10Q50716216-C55E12A5-E54E-470C-9CBA-F1BB442B9509Q51246507-C66874CE-A6D7-43F6-B242-C0A13BF8FDF6Q55047684-226BE849-7F15-4CB1-9509-89ADE63698BCQ55293538-808F76AE-E3A2-40C4-9409-7FB3E768DB3DQ56529954-27152307-EB06-411E-8E23-8802FD7E0BA2Q58769905-D22A0300-9D24-4B4D-913D-0BC2B607FB1CQ59361961-A066B0BD-C2D3-472E-A6C2-4E34882072A8Q64086267-51936E4A-4BA5-4F73-88D1-80295D860498Q84523209-F92D1651-AA75-47E7-9DCE-EE06E7739210
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Wendy A Davis
@ast
Wendy A Davis
@en
Wendy A Davis
@es
Wendy A Davis
@nl
Wendy A Davis
@sl
type
label
Wendy A Davis
@ast
Wendy A Davis
@en
Wendy A Davis
@es
Wendy A Davis
@nl
Wendy A Davis
@sl
prefLabel
Wendy A Davis
@ast
Wendy A Davis
@en
Wendy A Davis
@es
Wendy A Davis
@nl
Wendy A Davis
@sl
P106
P1153
7402806940
P31
P496
0000-0002-5709-8235